Literature DB >> 8532022

Mismatches of minor histocompatibility antigens between HLA-identical donors and recipients and the development of graft-versus-host disease after bone marrow transplantation.

E Goulmy1, R Schipper, J Pool, E Blokland, J H Falkenburg, J Vossen, A Gratwohl, G B Vogelsang, H C van Houwelingen, J J van Rood.   

Abstract

BACKGROUND: Graft-versus-host disease (GVHD) can be a major complication of allogeneic bone marrow transplantation even when the donor and recipient are siblings and share identical major histocompatibility antigens. The explanation may be a mismatch of minor histocompatibility antigens. We previously characterized five minor histocompatibility antigens, HA-1, 2, 3, 4, and 5, that are recognized by T cells in association with the major histocompatibility antigens HLA-A1 an A2.
METHODS: We collected peripheral-blood leukocytes from 148 bone marrow recipients and their sibling donors, who were genotypically HLA identical. Fifty pairs were positive for HLA-A1, 117 were positive for HLA-A2, and 19 were positive for both. The pairs were typed with cytotoxic-T-cell clones specific for minor histocompatibility antigens HA-1, 2, 3, 4, and 5.
RESULTS: Mismatches of HA-3 were equally distributed among recipients in whom GVHD developed and those in whom it did not. By contrast, a mismatch of only HA-1 was significantly correlated with GVHD of grade II or higher (odds ratio, infinity; P = 0.02) in adults. One or more mismatches of HA-1, 2, 4, and 5 were also significantly associated with GVHD (odds ratio, infinity; P = 0.006) in adults. These associations were not observed in children.
CONCLUSIONS: A mismatch of minor histocompatibility antigen HA-1 can cause GVHD in adult recipients of allogeneic bone marrow from HLA-identical donors. Prospective HA-1 typing may improve donor selection and identify recipients who are at high risk for GVHD.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8532022     DOI: 10.1056/NEJM199602013340501

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  97 in total

1.  [Cutaneous graft-versus-host disease].

Authors:  S Karrer
Journal:  Hautarzt       Date:  2003-05       Impact factor: 0.751

2.  Minor histocompatibility antigens are expressed in syncytiotrophoblast and trophoblast debris: implications for maternal alloreactivity to the fetus.

Authors:  Olivia J Holland; Caitlin Linscheid; Herbert C Hodes; Traci L Nauser; Melissa Gilliam; Peter Stone; Larry W Chamley; Margaret G Petroff
Journal:  Am J Pathol       Date:  2011-11-08       Impact factor: 4.307

3.  Effects of allogeneic hematopoietic stem cell transplantation plus thymus transplantation on malignant tumors: comparison between fetal, newborn, and adult mice.

Authors:  Yuming Zhang; Naoki Hosaka; Yunze Cui; Ming Shi; Susumu Ikehara
Journal:  Stem Cells Dev       Date:  2010-09-13       Impact factor: 3.272

Review 4.  Prevention of graft-vs.-host disease.

Authors:  Andrew R Rezvani; Rainer F Storb
Journal:  Expert Opin Pharmacother       Date:  2012-07-07       Impact factor: 3.889

5.  Sensitization to minor antigens is a significant barrier in bone marrow transplantation and is prevented by CD154:CD40 blockade.

Authors:  H Xu; Y Huang; L R Hussain; Z Zhu; L D Bozulic; C Ding; J Yan; S T Ildstad
Journal:  Am J Transplant       Date:  2010-07       Impact factor: 8.086

6.  Identification of an immunodominant mouse minor histocompatibility antigen (MiHA). T cell response to a single dominant MiHA causes graft-versus-host disease.

Authors:  C Perreault; J Jutras; D C Roy; J G Filep; S Brochu
Journal:  J Clin Invest       Date:  1996-08-01       Impact factor: 14.808

7.  Acute graft versus host disease due to T lymphocytes recognizing a single HLA-DPB1*0501 mismatch.

Authors:  J Gaschet; A Lim; L Liem; R Vivien; M M Hallet; J L Harousseau; J Even; E Goulmy; M Bonneville; N Milpied; H Vié
Journal:  J Clin Invest       Date:  1996-07-01       Impact factor: 14.808

8.  Characterization of T cell repertoire in patients with graft-versus-leukemia after donor lymphocyte infusion.

Authors:  E J Claret; E P Alyea; E Orsini; C C Pickett; H Collins; Y Wang; D Neuberg; R J Soiffer; J Ritz
Journal:  J Clin Invest       Date:  1997-08-15       Impact factor: 14.808

Review 9.  Targeting minor histocompatibility antigens in graft versus tumor or graft versus leukemia responses.

Authors:  Xin Feng; Kwok Min Hui; Hashem M Younes; Anthony G Brickner
Journal:  Trends Immunol       Date:  2008-10-25       Impact factor: 16.687

10.  Long-term in vivo provision of antigen-specific T cell immunity by programming hematopoietic stem cells.

Authors:  Lili Yang; David Baltimore
Journal:  Proc Natl Acad Sci U S A       Date:  2005-03-09       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.